Current strategic thinking for the development of a trivalent alphavirus vaccine for human use

Vaccinations against the encephalitic alphaviruses (western, eastern, and Venezuelan equine encephalitis virus) are of significant interest to biological defense, public health, and agricultural communities alike. Although vaccines licensed for veterinary applications are used in the Western Hemisph...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of tropical medicine and hygiene 2014-09, Vol.91 (3), p.442-450
Main Authors: Wolfe, Daniel N, Heppner, D Gray, Gardner, Shea N, Jaing, Crystal, Dupuy, Lesley C, Schmaljohn, Connie S, Carlton, Kevin
Format: Article
Language:English
Subjects:
Alphavirus
Alphavirus - genetics
Alphavirus - immunology
Alphavirus Infections - prevention & control
Alphavirus Infections - virology
Animals
Encephalitis Virus, Eastern Equine - genetics
Encephalitis Virus, Eastern Equine - immunology
Encephalitis Virus, Venezuelan Equine - genetics
Encephalitis Virus, Venezuelan Equine - immunology
Encephalitis Virus, Western Equine - genetics
Encephalitis Virus, Western Equine - immunology
Encephalitis, Viral - prevention & control
Encephalitis, Viral - virology
Humans
Piece
Sequence Alignment
Vaccination
Venezuelan equine encephalitis virus
Viral Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccinations against the encephalitic alphaviruses (western, eastern, and Venezuelan equine encephalitis virus) are of significant interest to biological defense, public health, and agricultural communities alike. Although vaccines licensed for veterinary applications are used in the Western Hemisphere and attenuated or inactivated viruses have been used under Investigational New Drug status to protect at-risk personnel, there are currently no licensed vaccines for use in humans. Here, we will discuss the need for a trivalent vaccine that can protect humans against all three viruses, recent progress to such a vaccine, and a strategy to continue development to Food and Drug Administration licensure.
ISSN:0002-9637
1476-1645
DOI:10.4269/ajtmh.14-0055